JP2014502141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014502141A5 JP2014502141A5 JP2013532226A JP2013532226A JP2014502141A5 JP 2014502141 A5 JP2014502141 A5 JP 2014502141A5 JP 2013532226 A JP2013532226 A JP 2013532226A JP 2013532226 A JP2013532226 A JP 2013532226A JP 2014502141 A5 JP2014502141 A5 JP 2014502141A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence shown
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 102000013498 tau Proteins Human genes 0.000 claims description 22
- 108010026424 tau Proteins Proteins 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 20
- 206010012289 Dementia Diseases 0.000 claims description 12
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 11
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 10
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 8
- 230000007170 pathology Effects 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 210000000349 chromosome Anatomy 0.000 claims description 5
- 230000007850 degeneration Effects 0.000 claims description 5
- 230000000750 progressive effect Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
- 201000010374 Down Syndrome Diseases 0.000 claims description 4
- 208000026072 Motor neurone disease Diseases 0.000 claims description 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims description 4
- 108091000054 Prion Proteins 0.000 claims description 4
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 4
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 4
- 208000034799 Tauopathies Diseases 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 206010044688 Trisomy 21 Diseases 0.000 claims description 4
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 230000003796 beauty Effects 0.000 claims description 4
- 230000002308 calcification Effects 0.000 claims description 4
- 208000017004 dementia pugilistica Diseases 0.000 claims description 4
- 201000008319 inclusion body myositis Diseases 0.000 claims description 4
- 230000003902 lesion Effects 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims description 4
- 230000002739 subcortical effect Effects 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 208000033556 type C1 Niemann-Pick disease Diseases 0.000 claims description 4
- 206010018341 Gliosis Diseases 0.000 claims description 3
- 230000007387 gliosis Effects 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 41
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 10
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 10
- 210000004408 hybridoma Anatomy 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 102000057063 human MAPT Human genes 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100034452 Alternative prion protein Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 230000000875 corresponding effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001898 pallidal effect Effects 0.000 claims 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 description 5
- 208000004434 Calcinosis Diseases 0.000 description 3
- 102000029797 Prion Human genes 0.000 description 3
- 206010059245 Angiopathy Diseases 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10186810.7 | 2010-10-07 | ||
| EP10186810 | 2010-10-07 | ||
| EP11174248.2 | 2011-07-15 | ||
| EP11174248 | 2011-07-15 | ||
| PCT/EP2011/067604 WO2012045882A2 (en) | 2010-10-07 | 2011-10-07 | Pharmaceutical composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017008740A Division JP2017113004A (ja) | 2010-10-07 | 2017-01-20 | 薬学的組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014502141A JP2014502141A (ja) | 2014-01-30 |
| JP2014502141A5 true JP2014502141A5 (enExample) | 2016-06-23 |
| JP6371526B2 JP6371526B2 (ja) | 2018-08-08 |
Family
ID=44947048
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013532226A Active JP6371526B2 (ja) | 2010-10-07 | 2011-10-07 | タウを認識するリン酸化部位特異的抗体 |
| JP2017008740A Pending JP2017113004A (ja) | 2010-10-07 | 2017-01-20 | 薬学的組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017008740A Pending JP2017113004A (ja) | 2010-10-07 | 2017-01-20 | 薬学的組成物 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US9304138B2 (enExample) |
| EP (2) | EP2625198B1 (enExample) |
| JP (2) | JP6371526B2 (enExample) |
| KR (1) | KR101988672B1 (enExample) |
| CN (1) | CN103502272B (enExample) |
| AR (1) | AR085198A1 (enExample) |
| AU (1) | AU2011311516B2 (enExample) |
| BR (1) | BR112013008333B1 (enExample) |
| CA (1) | CA2812865C (enExample) |
| CL (1) | CL2013000951A1 (enExample) |
| CO (1) | CO6710903A2 (enExample) |
| CR (1) | CR20130160A (enExample) |
| DK (1) | DK2625198T3 (enExample) |
| EC (1) | ECSP13012609A (enExample) |
| ES (1) | ES2548686T3 (enExample) |
| HK (1) | HK1216897A1 (enExample) |
| HU (1) | HUE027649T2 (enExample) |
| IL (1) | IL225568A (enExample) |
| MX (1) | MX338421B (enExample) |
| MY (1) | MY164376A (enExample) |
| PE (1) | PE20140218A1 (enExample) |
| PH (1) | PH12013500615A1 (enExample) |
| PL (1) | PL2625198T3 (enExample) |
| RU (1) | RU2603078C2 (enExample) |
| SG (1) | SG189136A1 (enExample) |
| SI (1) | SI2625198T1 (enExample) |
| TW (1) | TW201216985A (enExample) |
| WO (1) | WO2012045882A2 (enExample) |
| ZA (1) | ZA201302432B (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10266585B2 (en) * | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| EP2625198B1 (en) * | 2010-10-07 | 2015-07-22 | AC Immune S.A. | Antibodies recognising phospho-tau |
| US8940272B2 (en) | 2010-10-11 | 2015-01-27 | University Of Zurich | Human anti-tau antibodies |
| CA2826286C (en) | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| ES2655051T3 (es) | 2011-08-26 | 2018-02-16 | Wisconsin Alumni Research Foundation | Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas |
| CN108034005B (zh) | 2011-10-07 | 2021-06-25 | Ac免疫有限公司 | 识别Tau的磷酸化特异抗体 |
| DK2794654T3 (da) * | 2011-12-20 | 2019-08-05 | Janssen Biotech Inc | Anti-phf-tau-antistoffer og deres anvendelser |
| EP2834270B1 (en) | 2012-04-05 | 2019-10-30 | AC Immune S.A. | Humanized tau antibody |
| SG10201913370PA (en) | 2012-07-03 | 2020-03-30 | Univ Washington | Antibodies to tau |
| WO2014016737A1 (en) * | 2012-07-24 | 2014-01-30 | Pfizer Inc. | Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof |
| SI2885010T1 (sl) | 2012-08-16 | 2020-07-31 | Ipierian, Inc. | Metode zdravljenja tauopatije |
| US12024568B2 (en) | 2012-09-13 | 2024-07-02 | Cornell University | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| BR112015014751A8 (pt) | 2012-12-21 | 2018-01-16 | Biogen Int Neuroscience Gmbh | anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos. |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| US9598485B2 (en) | 2013-03-15 | 2017-03-21 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
| JP6824735B2 (ja) | 2013-06-06 | 2021-02-03 | ピエール、ファーブル、メディカマン | 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法 |
| GB201312226D0 (en) * | 2013-07-08 | 2013-08-21 | Adx Neurosciences | Improved antibodies |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| WO2015081085A2 (en) * | 2013-11-27 | 2015-06-04 | Ipierian, Inc. | Methods of treating a tauopathy |
| AU2014368696A1 (en) | 2013-12-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Humanized anti-Tau(pS422) antibodies and methods of use |
| CN105939722A (zh) | 2014-02-14 | 2016-09-14 | 伊皮埃里安股份有限公司 | Tau肽，抗Tau抗体，及其使用方法 |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗－ｔａｕ抗體 |
| KR102502356B1 (ko) | 2014-09-30 | 2023-02-21 | 워싱턴 유니버시티 | 타우 (tau) 활동 계측 |
| ES2848376T3 (es) * | 2014-11-19 | 2021-08-09 | Axon Neuroscience Se | Anticuerpos de tau humanizados en la enfermedad de Alzheimer |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| JO3576B1 (ar) | 2015-02-26 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لـ tau واستخداماتها |
| UA126272C2 (uk) | 2015-06-05 | 2022-09-14 | Дженентек, Інк. | Антитіло проти тау-білка та спосіб його застосування |
| CN113929779B (zh) | 2015-06-24 | 2025-02-25 | 豪夫迈·罗氏有限公司 | 人源化的抗-Tau(pS422)抗体和使用方法 |
| MA41670A1 (fr) | 2015-07-06 | 2018-05-31 | Ucb Biopharma Sprl | Anticorps se liant a tau |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| WO2017027691A1 (en) | 2015-08-13 | 2017-02-16 | New York University | Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
| AU2017221444B2 (en) | 2016-02-19 | 2021-07-29 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza B virus replication for vaccine development |
| NZ748983A (en) * | 2016-07-12 | 2022-12-23 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
| CA3032692A1 (en) | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination antibody therapy for the treatment of neurodegenerative diseases |
| CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| MX2019006334A (es) | 2016-12-07 | 2019-08-01 | Genentech Inc | Anticuerpos antitau y métodos de uso. |
| JP7217710B2 (ja) * | 2017-01-04 | 2023-02-03 | ハー・ルンドベック・アクチエゼルスカベット | 眼疾患の治療のための過リン酸化タウに特異的な抗体 |
| JP2020508054A (ja) | 2017-02-17 | 2020-03-19 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 抗タウ抗体及びその使用方法 |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| EA039569B1 (ru) * | 2017-03-14 | 2022-02-11 | Х. Лундбекк А/С | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения |
| JOP20180021A1 (ar) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
| WO2018217630A1 (en) * | 2017-05-21 | 2018-11-29 | University Of Tennessee Research Foundation | Methods and compositions for targeting tissue lesions |
| UA129617C2 (uk) | 2017-10-16 | 2025-06-18 | Еісаі Р Енд Д Менеджмент Ко., Лтд. | Антитіло до тау та його застосування |
| US11197926B2 (en) | 2017-10-25 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| WO2019107370A1 (ja) * | 2017-11-28 | 2019-06-06 | 国立大学法人三重大学 | 検出方法 |
| AU2019232631A1 (en) | 2018-03-05 | 2020-09-24 | Janssen Pharmaceutica Nv | Anti-PHF-tau antibodies and uses thereof |
| EP3829634A1 (en) | 2018-07-31 | 2021-06-09 | Eli Lilly and Company | Combination therapy |
| US12343390B2 (en) | 2018-08-07 | 2025-07-01 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| US11389523B2 (en) | 2018-08-20 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein |
| US12116415B2 (en) * | 2018-10-09 | 2024-10-15 | Single Cell Technology, Inc. | Anti-BCMA antibodies |
| AU2018446059A1 (en) * | 2018-10-17 | 2021-05-20 | The University Of Queensland | Methods and compositions for treating tauopathies |
| CA3118692A1 (en) | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
| EP3906055A4 (en) * | 2019-01-04 | 2023-01-04 | Trio Pharmaceuticals, Inc. | MULTISPECIFIC PROTEIN MOLECULES AND THEIR USES |
| CN113874496A (zh) | 2019-02-08 | 2021-12-31 | 威斯康星校友研究基金会(Warf) | 人源化细胞系 |
| CA3135170A1 (en) | 2019-04-05 | 2020-10-08 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
| EP3953392A1 (en) * | 2019-04-12 | 2022-02-16 | Phanes Therapeutics, Inc. | Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof |
| WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| CN110028583B (zh) * | 2019-05-07 | 2020-09-11 | 温州医科大学 | 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用 |
| JP7627911B2 (ja) | 2019-08-27 | 2025-02-07 | ウィスコンシン アルムニ リサーチ ファンデイション | 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス |
| CN112752251B (zh) | 2019-10-29 | 2022-05-06 | 中国移动通信有限公司研究院 | 一种ue标识符的分配方法、装置和计算机可读存储介质 |
| WO2021150874A1 (en) | 2020-01-24 | 2021-07-29 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized na |
| AU2021217290A1 (en) * | 2020-02-05 | 2022-07-21 | Sumitomo Pharma Co., Ltd. | Determination agent and determination method for tauopathy and dementia-related diseases |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| US20230265175A1 (en) | 2020-06-25 | 2023-08-24 | Merck Sharp & Dohme Llc | High affinity antibodies targeting tau phosphorylated at serine 413 |
| AU2021403010A1 (en) * | 2020-12-16 | 2023-07-13 | Voyager Therapeutics, Inc. | Tau binding compounds |
| EP4014997A1 (en) | 2020-12-16 | 2022-06-22 | Consejo Superior de Investigaciones Científicas (CSIC) | Stard1 inhibitors for the treatment of lysosomal disorders |
| MX2023010813A (es) * | 2021-03-18 | 2023-09-27 | Seagen Inc | Anticuerpos anti-alpp/alppl2 y conjugados de anticuerpo-farmaco. |
| CL2021001380A1 (es) | 2021-05-26 | 2022-01-14 | Corporacion Centro Int De Biomedicina Icc | Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias. |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| KR20250069606A (ko) | 2022-09-15 | 2025-05-19 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| EP4658689A2 (en) * | 2023-02-02 | 2025-12-10 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Phosphomimetic mutants, phosphospecific antibodies, and uses thereof |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025128975A1 (en) * | 2023-12-14 | 2025-06-19 | Immunitas Therapeutics, Inc. | Cd161 binding proteins and related methods |
| WO2025134068A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Antibody drug conjugates targeting proteinopathies, and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| ATE386115T1 (de) | 1991-12-06 | 2008-03-15 | Max Planck Gesellschaft | Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit |
| AU677216B2 (en) | 1992-07-27 | 1997-04-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Targeting of liposomes to the blood-brain barrier |
| ES2176342T5 (es) | 1994-10-21 | 2010-02-09 | Innogenetics N.V. | Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacion como agentes profilacticos, terapeuticos y de diagnosticos. |
| US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
| US20020086009A1 (en) * | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
| WO1998022120A1 (en) * | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| AU2001273361A1 (en) * | 2000-07-11 | 2002-01-21 | Molecular Geriatrics Corporation | Reagents and methods for identification of binding agents |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| EP2147679B1 (en) | 2001-07-25 | 2014-06-25 | Raptor Pharmaceutical, Inc. | Compositions for blood-brain barrier transport |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7220833B2 (en) | 2002-12-03 | 2007-05-22 | Thomas Nelson | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
| NZ541282A (en) | 2002-12-24 | 2009-02-28 | Bellus Health International Ltd | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| JP2007505142A (ja) | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 |
| US7238788B2 (en) | 2004-02-18 | 2007-07-03 | University Of Iowa Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| NZ554725A (en) | 2004-10-25 | 2009-10-30 | Merck & Co Inc | Anti-ADDL antibodies and uses thereof |
| US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20080220449A1 (en) | 2007-02-08 | 2008-09-11 | Oligomerix, Inc. | Biomarkers and assays for Alzheimer's disease |
| US9555032B2 (en) | 2007-06-13 | 2017-01-31 | Research Development Foundation | Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling |
| EP2210901A4 (en) * | 2007-10-19 | 2012-04-25 | Immunas Pharma Inc | FOR THE SPECIFIC BINDING TO AN OLIGOMICALLY ABLE ANTIBODY AND ITS USE |
| DK2408807T3 (da) | 2009-03-18 | 2021-08-09 | Ac Immune Sa | Fremgangsmåde til terapeutisk anvendelse |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| WO2010144711A2 (en) * | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| IN2012DN00446A (enExample) | 2009-07-30 | 2015-05-15 | Pfizer Vaccines Llc | |
| EP2625198B1 (en) * | 2010-10-07 | 2015-07-22 | AC Immune S.A. | Antibodies recognising phospho-tau |
-
2011
- 2011-10-07 EP EP11773704.9A patent/EP2625198B1/en active Active
- 2011-10-07 AU AU2011311516A patent/AU2011311516B2/en active Active
- 2011-10-07 EP EP15177523.6A patent/EP2987807A3/en not_active Withdrawn
- 2011-10-07 PH PH1/2013/500615A patent/PH12013500615A1/en unknown
- 2011-10-07 DK DK11773704.9T patent/DK2625198T3/en active
- 2011-10-07 MY MYPI2013700539A patent/MY164376A/en unknown
- 2011-10-07 CA CA2812865A patent/CA2812865C/en active Active
- 2011-10-07 TW TW100136670A patent/TW201216985A/zh unknown
- 2011-10-07 CN CN201180058969.9A patent/CN103502272B/zh active Active
- 2011-10-07 SI SI201130615T patent/SI2625198T1/sl unknown
- 2011-10-07 RU RU2013120544/10A patent/RU2603078C2/ru active
- 2011-10-07 HU HUE11773704A patent/HUE027649T2/en unknown
- 2011-10-07 MX MX2013003800A patent/MX338421B/es active IP Right Grant
- 2011-10-07 PL PL11773704T patent/PL2625198T3/pl unknown
- 2011-10-07 JP JP2013532226A patent/JP6371526B2/ja active Active
- 2011-10-07 ES ES11773704.9T patent/ES2548686T3/es active Active
- 2011-10-07 BR BR112013008333-6A patent/BR112013008333B1/pt active IP Right Grant
- 2011-10-07 KR KR1020137011715A patent/KR101988672B1/ko active Active
- 2011-10-07 US US13/500,608 patent/US9304138B2/en active Active
- 2011-10-07 PE PE2013000800A patent/PE20140218A1/es not_active Application Discontinuation
- 2011-10-07 WO PCT/EP2011/067604 patent/WO2012045882A2/en not_active Ceased
- 2011-10-07 SG SG2013023031A patent/SG189136A1/en unknown
- 2011-10-11 AR ARP110103735A patent/AR085198A1/es unknown
-
2013
- 2013-03-04 ZA ZA2013/02432A patent/ZA201302432B/en unknown
- 2013-04-04 IL IL225568A patent/IL225568A/en active IP Right Grant
- 2013-04-05 CR CR20130160A patent/CR20130160A/es unknown
- 2013-04-05 CO CO13089514A patent/CO6710903A2/es unknown
- 2013-04-08 CL CL2013000951A patent/CL2013000951A1/es unknown
- 2013-05-07 EC ECSP13012609 patent/ECSP13012609A/es unknown
-
2016
- 2016-02-17 US US15/045,804 patent/US10100104B2/en active Active
- 2016-04-25 HK HK16104710.3A patent/HK1216897A1/en unknown
-
2017
- 2017-01-20 JP JP2017008740A patent/JP2017113004A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014502141A5 (enExample) | ||
| RU2014118456A (ru) | Фосфоспецифичные антитела, распознающие тау | |
| IL225568A (en) | Phospho-specific antibodies for tau detection | |
| RU2014144331A (ru) | Гуманизированное тау-антитело | |
| JP7109467B2 (ja) | タウに特異的に結合する結合分子 | |
| JP2012530055A5 (enExample) | ||
| JP2019059786A (ja) | 神経変性障害の処置のためのセマフォリン−４ｄ結合分子の使用 | |
| JP7626416B2 (ja) | 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法 | |
| JP2017113004A5 (enExample) | ||
| JP6263473B2 (ja) | 脳における高レベルのα−シヌクレインを診断するための抗α−シヌクレイン抗体の使用 | |
| JP2015532592A5 (enExample) | ||
| JP2018505651A5 (enExample) | ||
| JP2018535921A5 (enExample) | ||
| CN116348487A (zh) | 抗淀粉样β抗体 | |
| CN108431039B (zh) | 改进的p2x7受体结合剂和包含其的多肽 | |
| JP2021119781A (ja) | 微小管結合タンパク質タウに特異的に結合する抗体及び抗原結合断片 | |
| TW202434629A (zh) | 以抗類澱粉β (ABETA)抗體治療神經病症之方法 | |
| CN111655723A (zh) | 与tau特异性结合的结合分子 | |
| TW202541846A (zh) | 以抗類澱粉蛋白β (ABETA)抗體治療神經病症之方法 | |
| WO2025240435A1 (en) | Methods of treating neurological disorders with anti-abeta antibodies | |
| HK40113703A (zh) | 神经变性疾病的治疗剂 | |
| WO2026025002A1 (en) | Methods of treating neurological disorders with anti-abeta antibodies | |
| CA3090356A1 (en) | Conformation-independent antibodies against neurotoxic tau proteins |